Kāpae

ʻO Canagliflozin kahi mea hou, ikaika, a koho nui i ka sodium glucose co-transporter (SGLT) 2 inhibitor [1]. Ua hōʻike ʻia ʻo Canagliflozin hiki ke hoʻonui i ka urine glucose excretion ma o ka hoʻohaʻahaʻa ʻana i ka paepae glucose renal a me ka hoʻohaʻahaʻa ʻana i ka kānana glucose re-absorption [2].

Ua hōʻike ʻia ʻo Canagliflozin e kāohi i ka Na + -mediated 14C-AMG intakes i CHO-hSGLT2, CHO-rat SGLT2 a me CHO-mouse SGLT2 me nā waiwai IC50 o 4.4, 3.7 a me 2.0 nM, kēlā me kēia [1].

Ua hōʻike ʻia ʻo Canagliflozin e hōʻemi i ke kiʻekiʻe o ka glucose koko (BG) ma muli o ka nui o nā ʻiole db/db a me Zucker diabetic fatty (ZDF) iole. Eia kekahi, ua hōʻike ʻo canagliflozin i ka hōʻemi ʻana i ka ratio hoʻololi hanu, a me ke kaumaha o ke kino i nā ʻiole DIO a me nā ʻiole ZDF [1].

Hiki ke lawe waha ʻia ʻo Canagliflozin [1].

Kuhikuhi:
[1] Liang Y1, Arakawa K, Ueta K, Matsushita Y, Kuriyama C Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Ka hopena o ka canagliflozin ma ka paepae renal no ka glucose, ka glycemia, a me ke kaumaha o ke kino i nā ʻano holoholona maʻamau a maʻi maʻi. PLoS Hoʻokahi. 2012;7(2):e30555
[2] ʻO Sarnoski-Brocavich S, Hilas O. Canagliflozin (Invokana), he ʻAgent Oral Novel No ka Diabetes Type-2. P T. 2013 Nov;38(11):656-66

Huahana Huahana

Bahia Abbas Moussa, Marianne Alphonse Mahrouse, et al. "ʻO nā ʻenehana hoʻonā like ʻole no ka hoʻokele ʻana i ka spectra overlapped: No ka hoʻoholo ʻana i nā lāʻau lapaʻau hypoglycemic i hoʻohui pū ʻia i loko o kā lākou ʻano lāʻau lapaʻau hui." Spectrochimica Acta Māhele A: Molecular and Biomolecular Spectroscopy Loaʻa ma ka pūnaewele 20 Iune 2018.

ʻO ke kinona